Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.
|Published (Last):||14 June 2018|
|PDF File Size:||13.77 Mb|
|ePub File Size:||1.23 Mb|
|Price:||Free* [*Free Regsitration Required]|
Dofetilide is a minor Lnsert substrate; however, because there is a linear relationship between dofetilide plasma concentration and QTc, concomitant administration of CYP3A4 inhibitors may increase the risk of arrhythmia torsade de pointes. Before switching from lidocaine to dofetilide therapy, lidocaine generally should be withheld for at least three half-lives prior to initiating dofetilide.
Severe Because of the potential for torsade de pointes TdPthe use of oxaliplatin with dofetilide is contraindicated. Severe Because of the potential for torsade de pointes TdPuse of macimorelin with dofetilide is pzckage.
TdP and ventricular tachycardia have inert reported during post-marketing use of anagrelide. Class I antiarrhythmic agents are contraindicated with dofetilide, and may increase the risk of dofetilide-induced proarrhythmias.
Administration of dofetilide requires a specialized care setting; treatment with dofetilide may be started only in doofetilide placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic ECG monitoring, and cardiac resuscitation. Because of the potential for TdP, use of dofetilide with tetrabenazine is contraindicated. It is not known if hemodialysis removes dofetilide from plasma.
The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is generally not recommended due to the potential risk for ventricular tachycardia, including Dofetilie and monomorphic ventricular tachycardia.
Severe Primaquine has the potential to prolong the QT interval. Hawthorn thus has effects similar to the class III antiarrhythmics and would theoretically interact with drugs with similar insrrt electrophysiology e.
Because of the potential for torsade de pointes TdPuse of dofetilide with olanzapine is contraindicated. Minor In vitro studies have demonstrated the positive inotropic effects of ginger, Zingiber officinale. Rare case reports of QT prolongation have also been described when tamoxifen is used at lower doses.
Before switching from moricizine to dofetilide therapy, moricizine generally dofetilise be withheld for at least three half-lives prior to initiating dofetilide.
We do not record any personal information entered above. Lofexidine prolongs the QT interval. Because of the potential for TdP, use of dofetilide with trazodone is contraindicated.
Severe Prolongation of insedt QT interval has been reported with administration of moxifloxacin. Following hawthorn administration to guinea pigs, the cardiac action potential duration is increased and the refractory period is prolonged. However, due to the lack of clinical data and the potential for torsade de pointes TdPuse of dofetilide with mefloquine is contraindicated. Clinicians should also evaluate any concomitant drug therapy for the potential to decrease the renal elimination of dofetilide.
Posaconazole is a potent inhibitor of CYP3A4, an isoenzyme dofetilidde for a portion of the metabolism of dofetilide. Dalfopristin; quinupristin is a weak CYP3A4 inhibitor.
Major Dofetilide should be co-administered with metformin with caution since both drugs are actively secreted via cationic secretion and could compete dofteilide common renal tubular transport systems. QT prolongation has occurred with both drugs, and dofetilide is also associated with a well-established risk for TdP.
Dofetilide is eliminated by cationic renal secretion, and tafenoquine may interfere with the renal elimination of dofetilide. Fingolimod initiation results in decreased heart rate, and Class III antiarrhythmic drugs have been associated with cases of torsades de pointes in patients with bradycardia.
Because of the potential for TdP, use of vardenafil with dofetilide is contraindicated. As a single mg or 40 mg oral dose, the inhibitory effect of aprepitant on CYP3A4 is weak, with the AUC of midazolam increased by 1.
QT prolongation and ventricular arrhythmias including fatal TdP have been reported with oxaliplatin use in post-marketing experience. Because of the potential for TdP, use of dofetilide with maprotiline is contraindicated. Moderate Monitor for an increase in dofetilide-related adverse reactions, including QT prolongation, if coadministration with everolimus is necessary.
Mefloquine alone has not been reported to cause QT prolongation.
The effect of vardenafil on the QT interval should be considered when prescribing the drug. Because of the potential for TdP, use of tricyclic antidepressants TCAs with dofetilide is contraindicated. Emtricitabine; Tenofovir disoproxil fumarate: Major Use caution if dofetilide and aprepitant, fosaprepitant are used concurrently and monitor for an increase in dofetilide-related adverse effects, including QT prolongation and torsade de pointes TdPfor several days after administration of a multi-day aprepitant regimen.
Major Diltiazem should be used with caution with dofetilide since it may increase dofetilide plasma concentrations via inhibition of CYP3A4 metabolism.